Webinar to be held January 25 at 16:00

This is in Standard Biotools’ (former Fluidigm) Scientist in the Spotlight series.

More info and registration on this link.

Hear about:

Insights into AML response: Discover the initial signaling response to standard induction chemotherapy in a cohort of 32 AML patients.

Predicting 5-year survival: Learn about the significant predictors of patient 5-year overall survival in this cohort, specifically the reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation.

Importance of signaling pathways: See how RNA sequencing and proteomics confirm the mass cytometry data and highlight the potential for this assay to be used in the future of precision oncology.